RhumbLine Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.62M | Buy |
517,255
+158,080
| +44% | +$800K | ﹤0.01% | 1742 |
|
|
2025
Q1 | $1.9M | Buy |
359,175
+25,143
| +8% | +$133K | ﹤0.01% | 1830 |
|
|
2024
Q4 | $2.26M | Buy |
334,032
+23,564
| +8% | +$159K | ﹤0.01% | 1828 |
|
|
2024
Q3 | $2.05M | Buy |
310,468
+29,120
| +10% | +$192K | ﹤0.01% | 1900 |
|
|
2024
Q2 | $2.11M | Buy |
281,348
+54,576
| +24% | +$409K | ﹤0.01% | 1856 |
|
|
2024
Q1 | $2.26M | Buy |
226,772
+7,705
| +4% | +$76.8K | ﹤0.01% | 1852 |
|
|
2023
Q4 | $2.16M | Sell |
219,067
-2,134
| -1% | -$21K | ﹤0.01% | 1860 |
|
|
2023
Q3 | $1.69M | Sell |
221,201
-36,774
| -14% | -$281K | ﹤0.01% | 1938 |
|
|
2023
Q2 | $1.93M | Buy |
257,975
+48,097
| +23% | +$359K | ﹤0.01% | 1920 |
|
|
2023
Q1 | $1.4M | Buy |
209,878
+4,291
| +2% | +$28.6K | ﹤0.01% | 1989 |
|
|
2022
Q4 | $1.59M | Buy |
205,587
+863
| +0.4% | +$6.65K | ﹤0.01% | 1909 |
|
|
2022
Q3 | $2.18M | Buy |
204,724
+16,058
| +9% | +$171K | ﹤0.01% | 1710 |
|
|
2022
Q2 | $1.54M | Buy |
188,666
+64,774
| +52% | +$527K | ﹤0.01% | 1909 |
|
|
2022
Q1 | $887K | Buy |
123,892
+4,818
| +4% | +$34.5K | ﹤0.01% | 2173 |
|
|
2021
Q4 | $2.04M | Buy |
119,074
+93,790
| +371% | +$1.61M | ﹤0.01% | 1871 |
|
|
2021
Q3 | $582K | Buy |
25,284
+4,466
| +21% | +$103K | ﹤0.01% | 2479 |
|
|
2021
Q2 | $760K | Buy |
+20,818
| New | +$760K | ﹤0.01% | 2367 |
|